Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
79.4M
-
Number of holders
-
155
-
Total 13F shares, excl. options
-
48.5M
-
Shares change
-
+1.96M
-
Total reported value, excl. options
-
$2.66B
-
Value change
-
+$143M
-
Put/Call ratio
-
0.67
-
Number of buys
-
102
-
Number of sells
-
-54
-
Price
-
$54.80
Significant Holders of Akero Therapeutics, Inc. - COMMON STOCK (AKRO) as of Q4 2022
202 filings reported holding AKRO - Akero Therapeutics, Inc. - COMMON STOCK as of Q4 2022.
Akero Therapeutics, Inc. - COMMON STOCK (AKRO) has 155 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 48.5M shares
of 79.4M outstanding shares and own 61.14% of the company stock.
Largest 10 shareholders include Avidity Partners Management LP (3.83M shares), JANUS HENDERSON GROUP PLC (3.34M shares), Skorpios Trust (3.27M shares), ALKEON CAPITAL MANAGEMENT LLC (3.24M shares), BlackRock Inc. (2.76M shares), Redmile Group, LLC (2.63M shares), STATE STREET CORP (2.5M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.4M shares), BAKER BROS. ADVISORS LP (2.37M shares), and VANGUARD GROUP INC (2.12M shares).
This table shows the top 155 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.